Should You Buy, Sell, or Hold Bio-Techne Shares After a Wealth Manager Completely Exits Its Position?

Hollow Brook Wealth Management Sells Entire Bio-Techne Stake

As detailed in a SEC filing dated February 17, 2026, Hollow Brook Wealth Management LLC liquidated its full holding in Bio-Techne (NASDAQ:TECH) during the last quarter of 2025. The firm sold 174,677 shares, with the transaction estimated at $10.7 million based on the average quarterly price.

Key Points

• Following the sale, Hollow Brook Wealth Management no longer holds any Bio-Techne shares, reducing its exposure to 0% of its 13F assets under management.
• Major investments after the filing include:
  • NYSEMKT: GLDM: $104.04 million (26.9% of AUM)
  • NASDAQ: DMLP: $17.96 million (4.6% of AUM)
  • NASDAQ: MSFT: $14.89 million (3.9% of AUM)
  • NASDAQ: GOOGL: $14.42 million (3.7% of AUM)
• Bio-Techne shares closed at $51.47 on March 13, 2026, marking a 12.68% decline over the previous year.

Bio-Techne Financial Highlights

Business Overview

• Bio-Techne specializes in the development and production of reagents, analytical devices, and diagnostic tools, including proteins, antibodies, assays, and molecular diagnostic kits.
• The company earns revenue by selling proprietary research products, diagnostic tests, and instruments to customers in both research and clinical sectors worldwide.
• Its clientele includes academic institutions, pharmaceutical and biotech firms, and clinical diagnostic organizations seeking advanced solutions for research, diagnostics, and therapeutic innovation.

Bio-Techne stands out as a prominent supplier of specialized reagents, analytical equipment, and diagnostic solutions for the life sciences and clinical diagnostics industries. Leveraging a wide array of proprietary brands and technologies, the company addresses complex challenges in research and clinical settings. Its strong foothold in protein sciences and diagnostics allows it to serve a diverse customer base and maintain a competitive edge in the global biotech market.

Implications for Investors

Hollow Brook's complete divestment from Bio-Techne is significant—not only due to the size of the transaction, but also because a total exit is more impactful than a partial reduction. When a fund eliminates a stock that previously made up 2.3% of its portfolio, it warrants further scrutiny.

Bio-Techne has faced challenges recently. Its stock has lagged the broader market by nearly 34 percentage points over the past year, affected by reduced spending from biopharma and biotech clients and slow revenue growth. The latest quarter showed stagnant revenue compared to the previous year, which may explain why wealth managers are moving on.

Looking Ahead: Is Bio-Techne Still a Good Investment?

However, a full exit doesn't necessarily mean the company is fundamentally flawed. Bio-Techne retains several strengths—about 80% of its revenue is recurring, it is well-regarded in protein sciences, and analysts on TipRanks have set an average price target of around $74, which is over 40% above the current share price. Additionally, Hollow Brook's largest remaining holding is a gold ETF, suggesting a shift toward more defensive or commodity-focused investments amid market uncertainty.

Should You Consider Buying Bio-Techne Shares?

Before investing in Bio-Techne, keep this in mind:

*Stock Advisor returns as of March 13, 2026.